Actinium Pharmaceuticals
ATNM
69 hedge funds and large institutions have $13.2M invested in Actinium Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 17 reducing their positions, and 9 closing their positions.
1,190% more call options, than puts
Call options by funds: $129K | Put options by funds: $10K
41% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 17
29% more capital invested
Capital invested by funds: $10.2M → $13.2M (+$2.95M)
0.21% more ownership
Funds ownership: 26.07% → 26.28% (+0.21%)
0% more funds holding
Funds holding: 69 → 69 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$390K |
| 2 |
GS
Gagnon Securities
New York
|
+$288K |
| 3 |
Invesco
Atlanta,
Georgia
|
+$179K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$95.3K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$59.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
-$231K |
| 2 |
Morgan Stanley
New York
|
-$191K |
| 3 |
Renaissance Technologies
New York
|
-$169K |
| 4 |
Millennium Management
New York
|
-$148K |
| 5 |
JP Morgan Chase
New York
|
-$130K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BOJHT
76
Bank of Jackson Hole Trust
Jackson,
Wyoming
| – | -$1.26K | -1,000 | Closed |
|
|
BL
77
BFSG LLC
Irvine,
California
| – | -$630 | -500 | Closed |
|
78
Citadel Advisors
Miami,
Florida
| – | -$378 | -298 | Closed |
|
ATNM Hedge Fund Activity: Q1 2025 in Review
69 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q1 2025, worth a combined $13.2M — up 29% from $10.2M a quarter earlier.
Fund positioning in ATNM was balanced in Q1 2025: 9 funds opened new positions, 9 closed out, 24 added to existing stakes and 17 trimmed.
The largest buyer was UBS Group, adding an estimated $390K. The largest seller was Squarepoint, exiting entirely with an estimated $231K sold.
- 69 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $13.2M of Actinium Pharmaceuticals stock for Q1 2025, up 29% quarter-over-quarter.
- 9 funds opened new Actinium Pharmaceuticals positions in Q1 2025 and 9 closed out, a net change of 0 holders.
- The largest Actinium Pharmaceuticals buyer in Q1 2025 was UBS Group, an estimated $390K added.
- The largest Actinium Pharmaceuticals seller in Q1 2025 was Squarepoint, an estimated $231K sold.
Based on aggregated 13F filings for Q1 2025.